Classical nodular sclerosis Hodgkin lymphoma presenting with atypical cardiac involvement

Georgiana Butura, Ion Antohe, Catalin Danaila, Alexandru Gluvacov, Dan Ferariu, Mugurel Bosanceanu, Angelica Slatineanu, Amalia Merticariu, Walther Bild, Angela Dascalescu


Primary and secondary cardiac involvements in lymphomas are extremely rare and sometimes ill-defined entities. Thorough clinical and imagistic investigation is crucial to evaluate disease extension and its impact on cardiac function. Chemotherapeutic agents with potential cardiovascular toxicity must be cautiously employed in high risk patients. We present the case of a young female patient with classical limited stage Hodgkin lymphoma and unfavorable prognostic factors, cardiac tumor mass with significant mediastinal extension, pleural effusion and subsequent cardiac dysfunction. Potentially cardiotoxic ABVD regimen yielded complete remission and progressive reversal of parameters of cardiac function.


Hodgkin lymphoma, cardiac tumor, Doxorubicin

Full Text:



Amano J, Nakayama J, Yoshimura Y, Ikeda U. Clinical classification of cardiovascular tumors and tumor-likelesions, and its incidences. Gen Thorac Cardiovasc Surg 2013; 61:435–447.

Butany J, Nair V, Naseemuddin A, Nair GM, Catton C, Yau T. Cardiac tumours: diagnosis and management. Lancet Oncol 2005; 6:219–228.

Maraj S, Pressman GS, Figueredo VM et al. Review Primary Cardiac Tumors. Int J Cardiol 2009; 133:152–156.

Miguel CE, Bestetti RB. Primary cardiac lymphoma. Int J Cardiol 2011; 149:358–363.

Amirimoghaddam Z, Khoddami M, Nayeri ND, Molaee S. Hodgkin’s lymphoma presenting with heart failure: a case report. J Med Case Rep 2010; 4:14.

Rolla G, Calligaris-Cappio F, Burke AP. Cardiac lymphomas. In Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC (eds.) World Health Organization. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004:282–286.

Petrich A, Cho SI, Billett H. Primary cardiac lymphoma: an analysis of presentation, treatment, and outcome patterns. Cancer 2011; 17(3):581-589.

Habertheuer A, Ehrlich M, Wiedemann D, Mora B, Rath C, Kocher A. A rare case of primary cardiac B cell lymphoma. J Cardiothorac Surg 2014; 9:14.

Leja MJ, Shah DJ, Reardon MJ. Primary Cardiac Tumors. Tex Heart Inst J 2011; 38(3):261–262.

Expert Group on Biomarkers. Biomarkers in Cardiology – Part 1 – In Heart Failure and Specific Cardiomyopathies. Arq Bras Cardiol 2014; 103(6):451–459.

Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989; 7(11):1630-1636.

Engert A, Eichenauer DA, Dreyling M; ESMO Guidelines Working Group. Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 2010; 21(5):168-171.

Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology Am Soc Hematol Educ Program 2009; 523-531.

National Comprehensive Cancer Network. Hodgkin’s Lymphoma in NCCN Clinical Practice Guidelines in Oncology. V.2.2015.

Holladay AO, Siegel RJ, Schwartz DA. Cardiac malignantlymphoma in acquired immune deficiency syndrome. Cancer 1992; 70:2203-2207.

Montalbetti L, Della Volpe A, Airaghi ML, Landoni C, Brambilla-Pisoni G, Pozzi S. Primary cardiac lymphoma.A case report and review. Minerva Cardioangiol 1999; 47:175-182.

Timóteo AT, Gouveia R, Gonçalves PA et al. Lymphoma with Clinical Presentation of a Primary Pericardial Tumor. Rev Port Cardiol 2003; 22(11):1385-1391.

Eich HT, Diehl V, Görgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J ClinOncol 2010; 28(27):4199-4206.

Volkova M, Russell R. Anthracycline Cardiotoxicity: Prevalence, Pathogenesis and Treatment. Curr Cardiol Rev 2011; 7:214-220.

Zuppinger C, Timolati F, Suter TM. Pathophysiology and diagnosis of cancer drug induced cardiomyopathy. Cardiovasc Toxicol 2007; 7:61-66.

Hochster HS. Clinical pharmacology of dexrazoxane. Semin Oncol 1998; 25(10):37-42.

Cardinale D, Sandri MT, Martinoni A. Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy. Ann Oncol 2002; 13(5):710-715.


Copyright (c) 2016 Archive of Clinical Cases

Creative Commons License
Archive of Clinical Cases is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.


ISSN: 2360-6975